Asset Details
Do you wish to reserve the book?
The association between acute transverse myelitis and COVID‐19 vaccination in Korea: Self‐controlled case series study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The association between acute transverse myelitis and COVID‐19 vaccination in Korea: Self‐controlled case series study
Do you wish to request the book?
The association between acute transverse myelitis and COVID‐19 vaccination in Korea: Self‐controlled case series study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The association between acute transverse myelitis and COVID‐19 vaccination in Korea: Self‐controlled case series study
2025
Overview
Background
Acute transverse myelitis (ATM) has been reported as a potential association between COVID‐19 vaccination. In this study, we aimed to investigate the association between the COVID‐19 vaccination and ATM.
Methods
A self‐controlled case series study was performed using a large database that combine the COVID‐19 vaccine registry and the national claims database. The COVID‐19 vaccination data included information on individuals aged 18 and above who received COVID‐19 vaccination from February 26, 2021, to August 31, 2022. The claims database covered the entire Korean population for the period between January 1, 2002 to August 31, 2022. Patients who develop ATM within 1–42 days following COVID‐19 vaccination were included. The observation period was 270 days after the first dose of the COVID‐19 vaccine. The incidence rate ratio (IRR) and 95% confidence interval (CI) were estimated using a conditional Poisson regression model.
Results
A total of 159 ATM patients were included. Among them, 82 (51.6%) were male, and mean age was 55.4 (±17.4) years. The IRR was 2.41 (95% CI: 1.76–3.30) for the ATM risk within 1–42 days after COVID‐19 vaccination. The IRR by vaccine product was 3.31 (95% CI: 1.81–6.05) for ChAdOx1‐S; 1.99 (95% CI: 1.30–3.03) for BNT162b2; 2.57 (95% CI: 1.14–5.97) for mRNA‐1273; and 3.33 (95% CI: 0.30–36.44) for Ad26.COV2.S.
Conclusion
These findings indicated an increased risk of ATM following COVID‐19 vaccination within 42 days. An association with the risk of ATM was found both for viral vector and mRNA vaccines.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc
Subject
/ Aged
/ COVID-19
/ COVID-19 - prevention & control
/ COVID-19 Vaccines - adverse effects
/ Female
/ Humans
/ Male
/ mRNA
/ Myelitis
/ Myelitis, Transverse - epidemiology
/ Myelitis, Transverse - etiology
/ Original
/ Republic of Korea - epidemiology
/ Risk
/ Vaccination - adverse effects
/ Vaccination - statistics & numerical data
/ Vaccines
